1092523-22-2

Basic information

• Product Name: 6-Chloro-2-(ethylaMino)pyridine-3-carbonyl Fluoride
• Synonyms: 6-Chloro-2-(ethylaMino)pyridine-3-carbonyl Fluoride
• CAS NO: 1092523-22-2
• Molecular Formula: C₈H₈ClFN₂O
• Molecular Weight: 202.6133232
• Product Categories: Amines, Heterocycles, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1092523-22-2.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Solubility: DCM
• CAS DataBase Reference: 6-Chloro-2-(ethylaMino)pyridine-3-carbonyl Fluoride(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-2-(ethylaMino)pyridine-3-carbonyl Fluoride(1092523-22-2)
• EPA Substance Registry System: 6-Chloro-2-(ethylaMino)pyridine-3-carbonyl Fluoride(1092523-22-2)

Safety Data

• Hazardous Substances Data: 1092523-22-2(Hazardous Substances Data)

Usage

Description

6-chloro-2-(ethylamino)pyridine-3-carbonyl fluoride is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals. It is characterized by its unique molecular structure, which includes a chloro group, an ethylamino group, and a pyridine ring with a carbonyl fluoride attached. 6-chloro-2-(ethylamino)pyridine-3-carbonyl fluoride plays a significant role in the development of targeted therapies for specific medical conditions.

Uses

Used in Pharmaceutical Industry:
6-chloro-2-(ethylamino)pyridine-3-carbonyl fluoride is used as an intermediate in the synthesis of SAR131675 (S139510), a potent and selective VEGFR-3 inhibitor. This application is significant because it targets the vascular endothelial growth factor receptor-3 (VEGFR-3), which is involved in the regulation of lymphatic and blood vessel formation. Inhibition of VEGFR-3 can potentially lead to the development of novel treatments for various conditions, including cancer and other diseases characterized by abnormal blood or lymphatic vessel growth.

Upstream product

• 675-14-9 trifluoro-[1,3,5]triazine 
• 1092523-21-1 6-chloro-2-(ethylamino)pyridine-3-carboxylic acid 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 

Downstream Products

• 1092523-24-4 2-amino-7-chloro-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1204651-82-0 2-amino-1-ethyl-7-{4-[2-({[(2S)-1-ethyl-4,4-difluoropyrrolidin-2-yl]methyl}-amino)-2-oxoethyl]phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1204651-66-0 2-amino-1-ethyl-7-{4-[2-({[(2S,4R)-1-ethyl-4-fluoropyrrolidin-2-yl]methyl}-amino)-2-oxoethyl]phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1204651-88-6 2-amino-1-ethyl-N-methyl-7-{4-[2-({[4-(1-methylethyl)morpholin-3-yl]-methyl}amino)-2-oxoethyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1204651-56-8 Ethyl {4-[7-amino-8-ethyl-6-(methylcarbamoyl)-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}acetate 
• 1204651-57-9 {4-[7-Amino-8-ethyl-6-(methyl carbamoyl)-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}acetic acid 
• 1204651-65-9 C₂₀H₁₉FN₄O₃ 
• 1204536-56-0 2-Amino-1-ethyl-4-oxo-7-[4-(3-pyridin-3-ylmethylureido)phenyl]-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid methylamide 
• 1412453-77-0 2-amino-7-(3-chloro-4-hydroxy-phenyl)-1-ethyl-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one 
• 1412453-78-1 2-Amino-1-ethyl-7-[3-(2-fluorophenyl)-3-hydroxybut-1-yn-1-yl]-3-(1H-imidazol-2-yl)-1,8-naphthyridin-4(1H)-one 
• 1412454-13-7 2-amino-7-(3-chloro-4-hydroxy-phenyl)-1-ethyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-1H-[1,8]naphthyridin-4-one 
• 1314069-32-3 2-amino-7-(4-{[(2,3-dichlorophenyl)sulfonyl]amino}-3-fluorophenyl)-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1308917-78-3 C₂₉H₃₇N₅O₄Si 
• 1308917-80-7 2-{4-[7-amino-8-ethyl-5-oxo-6-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}-N-[(4-cyclopropylmorpholin-3-yl)methyl]acetamide 

Relevant articles and documents

USE OF VEGFR-3 INHIBITORS FOR TREATING HEPATOCELLULAR CARCINOMA

This invention is related to the use of inhibitors of vascular endothelial growth factor receptor 3 for treating hepatocellular carcinoma.

ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF

The invention relates to pyridine-pyridinone derivatives general formula (I): in which R1, R2, R3, R4, n, n′, V, W, Y, Z, Ar are as defined in the description, and to their methods of preparation and their therapeutic applications.

2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors

The invention relates to the compounds of general formula (I): Preparation process and therapeutic use.